Category: Epidarex Portfolio News
Enterprise Therapeutics’ first-in-class TMEM16A potentiator program is a novel therapeutic approach applicable to all cystic fibrosis patients, independent of CFTR genotype, and may provide benefit in other respiratory diseases Epidarex Capital was the founding investor in Enterprise Therapeutics in 2015 and was instrumental in setting…
Post hoc analysis of Phase 2 FILLY study shows 39% reduction in rate of progression from nascent GA, an earlier form of disease, to GA in patients treated with pegcetacoplan monthly vs. sham First ever observation of slowed nascent GA progression in a Phase 2 study signals potential benefit of earlier intervention with pegcetacoplan in patients with GA Data support hypothesis that targeting C3 with pegcetacoplan addresses an underlying cause of disease,…
Libra Therapeutics is developing novel therapeutics for neurodegenerative diseases BETHESDA, MD (US) and EDINBURGH (UK), September 23, 2020 – Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, announces it has co-led the $29 Million Series A financing of Libra Therapeutics, Inc. together with Boehringer…
ETD002 is a novel TMEM16A chloride channel potentiator Therapy applicable to all cystic fibrosis patients, independent of genotype Brighton, UK, 17 August 2020: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients…
Novel immuno-therapies to overcome the resistance of existing cancer treatments Builds on the world-leading research into tumour associated macrophages (TAMs) Robert Haigh joins as CEO & Jane Dancer as NED Edinburgh, UK, July 14, 2020 – Macomics Ltd, an immuno-oncology company with world-leading expertise in…
Combines Best-in-Class Bone Repair with Intraoperative Ease-of-Use for Spine and Trauma Bone Grafting Applications Aberdeen, UK, 17 June 2020 – SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)…
71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria…
Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including…